Castration-resistant prostate cancer: potential targets and therapies

Aijaz Parray,1 Hifzur R Siddique,1 Sanjeev Nanda,1,2 Badrinath R Konety,3 Mohammad Saleem1,3,41Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, 2Department of Internal Medicine, Mayo Clinic Health Systems, Austin, TX, 3Department of Urology, Universi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Parray A, Siddique HR, Nanda S, Konety BR, Saleem M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/98be171ea8494abfa98366ad481bda40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:98be171ea8494abfa98366ad481bda40
record_format	dspace
spelling	oai:doaj.org-article:98be171ea8494abfa98366ad481bda402021-12-02T01:11:20ZCastration-resistant prostate cancer: potential targets and therapies1177-54751177-5491https://doaj.org/article/98be171ea8494abfa98366ad481bda402012-08-01T00:00:00Zhttp://www.dovepress.com/castration-resistant-prostate-cancer-potential-targets-and-therapies-a10732https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Aijaz Parray,1 Hifzur R Siddique,1 Sanjeev Nanda,1,2 Badrinath R Konety,3 Mohammad Saleem1,3,41Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, 2Department of Internal Medicine, Mayo Clinic Health Systems, Austin, TX, 3Department of Urology, University of Minnesota, Minneapolis, 4Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USAAbstract: The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.Keywords: chemoresistance, CRPC, molecular pathways, neoplastic prostateParray ASiddique HRNanda SKonety BRSaleem MDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 267-276 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Parray A Siddique HR Nanda S Konety BR Saleem M Castration-resistant prostate cancer: potential targets and therapies
description	Aijaz Parray,1 Hifzur R Siddique,1 Sanjeev Nanda,1,2 Badrinath R Konety,3 Mohammad Saleem1,3,41Molecular Chemoprevention and Therapeutics, The Hormel Institute, University of Minnesota, Austin, 2Department of Internal Medicine, Mayo Clinic Health Systems, Austin, TX, 3Department of Urology, University of Minnesota, Minneapolis, 4Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USAAbstract: The treatment landscape for patients with castration-resistant prostate cancer (CRPC) is undergoing significant changes with the advent of new therapies and multidisciplinary efforts by scientists and clinicians. As activation of multiple molecular pathways in the neoplastic prostate makes it impossible for single-target drugs to be completely effective in treating CRPC, this has led to combination therapy strategy, where several molecules involved in tumor growth and disease progression are targeted by a therapeutic regimen. In the present review, we provide an update on the molecular pathways that play an important role in the pathogenesis of CRPC and discuss the current wave of new treatments to combat this lethal disease.Keywords: chemoresistance, CRPC, molecular pathways, neoplastic prostate
format	article
author	Parray A Siddique HR Nanda S Konety BR Saleem M
author_facet	Parray A Siddique HR Nanda S Konety BR Saleem M
author_sort	Parray A
title	Castration-resistant prostate cancer: potential targets and therapies
title_short	Castration-resistant prostate cancer: potential targets and therapies
title_full	Castration-resistant prostate cancer: potential targets and therapies
title_fullStr	Castration-resistant prostate cancer: potential targets and therapies
title_full_unstemmed	Castration-resistant prostate cancer: potential targets and therapies
title_sort	castration-resistant prostate cancer: potential targets and therapies
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/98be171ea8494abfa98366ad481bda40
work_keys_str_mv	AT parraya castrationresistantprostatecancerpotentialtargetsandtherapies AT siddiquehr castrationresistantprostatecancerpotentialtargetsandtherapies AT nandas castrationresistantprostatecancerpotentialtargetsandtherapies AT konetybr castrationresistantprostatecancerpotentialtargetsandtherapies AT saleemm castrationresistantprostatecancerpotentialtargetsandtherapies
_version_	1718403273989292032

Castration-resistant prostate cancer: potential targets and therapies

Ejemplares similares